Summit Therapeutics has entered into an exclusive licence and commercialization agreement with Eurofarma Laboratórios, granting rights in Latin America to Summit's precision antibiotic ridinilazole in development for the treatment of CDI.
vTv Therapeutics has entered into a licensing agreement with Hangzhou Zhongmei Huadong Pharmaceutical for rights to develop and commercialize the former’s GLP-1r agonist program in China and other Pacific Rim countries.
MilliporeSigma has signed a commercial supply agreement to manufacture viral vectors for bluebird bio for use in potentially transformative gene therapies.
Cancer Research Technology (CRT), a subsidiary of Cancer Research UK, has entered into collaboration with American biopharmaceutical firm Celgene for the discovery, development and commercialization of new anti-cancer treatments.
Asklepios BioPharmaceutical has formed Actus Therapeutics, a new portfolio company based on AskBio’s industry-leading gene therapy platform.
Aerogen Pharma and Lyomark Pharma have partnered to develop a clinically superior treatment for Respiratory Distress Syndrome (RDS), a life-threatening condition of preterm infants associated with long-term lung health issues in survivors.
A new report from Persistence Market Research expects worldwide cryotherapy market to exceed $4bn by 2024.
bluebird bio and Scottish immunotherapy company TC BioPharm have partnered and signed a license agreement on gamma delta CAR T cells.
Gilead Sciences and its cell therapy subsidiary Kite have agreed to acquire Cell Design Labs, a biotherapeutics company that discovers and develops cell-based therapies, for about $567m.
Fate Therapeutics has partnered with the University of California San Diego to develop off-the-shelf, chimeric antigen receptor (CAR)-targeted natural killer (NK) cell cancer immunotherapies.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.